|
Welcome to Leukemia's online manuscript submission and tracking system. Please be sure that your browser is set to accept cookies as the tracking system requires these for proper operation. For more information please see Tips. If you are a first time user, please read our Instructions to Authors or Reviewers. Experienced users please remember passwords are case sensitive. **NEW Email Address**
Please note all correspondence regarding Leukemia should be sent to [email protected]. If you experience any problems, please contact the Platform Support Helpdesk.
Register for an account
Forgot my login details
Open Access
Leukemia is a hybrid journal. Authors can choose to publish using either the subscription publishing route OR via immediate gold Open Access through payment of an article-processing charge (APC).
Authors may need to take specific actions to achieve compliance with funder and institutional open access mandates. If your research is supported by a funder that requires immediate open access (e.g. according to Plan S principles or the NIH public access policy) then you should select the gold OA route, and we will direct you to the compliant route where possible. Because authors warrant under our subscription licensing terms that they haven't committed to licensing any version of their article under a licence inconsistent with the terms of our agreement - including the applicable embargo period - publication under the subscription model isn't suitable for authors whose funders require no embargo.
|